top of page

EC approves extended indication for Kyprolis in multiple myeloma

The European Commission (EC) has approved a variation to the marketing authorisation for Amgen’s Kyprolis (carfilzomib) to include use in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page